| 197.52 -4.01 (-1.99%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 248.44 | 1-year : | 290.18 |
| Resists | First : | 212.71 | Second : | 248.44 |
| Pivot price | 205.02 |
|||
| Supports | First : | 193.9  |
Second : | 182.27 |
| MAs | MA(5) : | 202.59 |
MA(20) : | 202.08 |
| MA(100) : | 183.2 |
MA(250) : | 161.25 |
|
| MACD | MACD : | 3.3 |
Signal : | 4.6 |
| %K %D | K(14,3) : | 30.5 |
D(3) : | 48.2 |
| RSI | RSI(14): 48.3 |
|||
| 52-week | High : | 212.71 | Low : | 121.41 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AZN ] has closed below the lower bollinger band by 10.5%. Bollinger Bands are 33.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 199.82 - 201.22 | 201.22 - 202.29 |
| Low: | 191.6 - 193.5 | 193.5 - 194.96 |
| Close: | 194.89 - 197.46 | 197.46 - 199.44 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Thu, 05 Mar 2026
AZN Stock News: Robbins LLP Reminds Investors of the Pending Lea - GuruFocus
Thu, 05 Mar 2026
HAP Trading LLC Sells 7,267 Shares of AstraZeneca PLC $AZN - MarketBeat
Thu, 05 Mar 2026
Mengis Capital Management Inc. Boosts Stock Position in AstraZeneca PLC $AZN - MarketBeat
Thu, 05 Mar 2026
Dimensional Fund Advisors LP Raises Stake in AstraZeneca PLC $AZN - MarketBeat
Wed, 04 Mar 2026
AstraZeneca (AZN) Strengthens Clinical Portfolio and Expands Inv - GuruFocus
Mon, 02 Mar 2026
AstraZeneca PLC (AZN) Investor Outlook: Evaluating the Healthcare Giant Amidst a -21.01% Potential Downside - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 1,550 (M) |
| Shares Float | 1,540 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 26.6 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 6.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 31.37 |
| Profit Margin | 17.4 % |
| Operating Margin | 19.5 % |
| Return on Assets (ttm) | 8 % |
| Return on Equity (ttm) | 22.8 % |
| Qtrly Rev. Growth | 4 % |
| Gross Profit (p.s.) | 30.94 |
| Sales Per Share | 37.89 |
| EBITDA (p.s.) | 12.58 |
| Qtrly Earnings Growth | 54.7 % |
| Operating Cash Flow | 14,570 (M) |
| Levered Free Cash Flow | 6,650 (M) |
| PE Ratio | 30.24 |
| PEG Ratio | 0 |
| Price to Book value | 6.29 |
| Price to Sales | 5.21 |
| Price to Cash Flow | 21.01 |
| Dividend | 1.01 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|